Click here for slides on this topic


Heart failure

Inability of the heart to provide sufficient pump action to distribute blood flow to meet the needs of the body.
The following content matched the glossary term: Heart failure

NDEI.org Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results

Top

Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients

NDEI.org Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths

Top

Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial

Top

The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary.

No Heart Failure Risk With DPP-4 Inhibitor, Sitagliptin, in TECOS Subanalysis

Top

Data from a subanalysis of TECOS at ESC Congress 2015 confirms that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes. Includes expert commentary.

NDEI.org Expert Commentary Vivian Fonseca, MD, on Results of TECOS, the Cardiovascular Safety Study of the DPP-4 Inhibitor Sitagliptin

Top

Vivian Fonseca provides expert insights on results of the TECOS cardiovascular safety study of the DPP-4 inhibitor, sitagliptin

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

NDEI.org Expert Commentary SAVOR-TIMI 53 Commentary from Silvio Inzucchi

Top

NDEI Education Council Member Silvio E. Inzucchi MD, comments on SAVOR TIMI 53: "Reassurance of the Overall Cardiovascular Safety of Saxagliptin and, One Might Infer, Other DPP 4 Inhibitors"

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

1 2 3 4 5 6 7 Next 

Slide Library Results

Search Results for: Heart failure Slides Found: 116
Incidence of Type 2 Diabetes-Related Vascular Disease in Four Ethnic Groups
Diabetes and Post-MI Survival in Two Ethnic Groups
Diabetes and Heart Failure: Current Knowledge
HF in Women >=65 Yr Old Strongly Associated With Preserved LVSF
Glycemic Control and Risk of Development of Heart Failure in Diabetes
Heart Failure Is More Common in Patients With Type 2 Diabetes
Adverse Events Associated With Thiazolidinedione Treatment
PROactive: Objective/Endpoints
PROactive: Heart Failure Events
ADOPT: Adverse Events
Hope: Design, Hypothesis, and Baseline Demographics
HOPE: Risk of Cardiovascular Events According to Microalbuminuria and Diabetes Status
Compelling Indications for Hypertension Drug Classes (1 of 2)
MICRO-HOPE: ACEI Reduces Risk of Nephropathy and CHF in Patients With Type 2 Diabetes
Cardiovascular Impact of Pioglitazone Therapy: A Meta-analysis
Long-term Risk of Heart Failure With Rosiglitazone: A Meta-analysis
Duration of TZD Therapy Prior to Onset of Heart Failure
Dose and Duration of TZD Therapy Prior to Onset of Heart Failure
ADVANCE: Death from Any Cause
VADT: Comparing Intensive With Standard Glucose Therapy, Primary Outcome
RECORD: CV Death and Hospitalization
RECORD: Conclusion
VADT: Primary Endpoint
VADT: Effect of BMI on Rates of Severe Hypoglycemia
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Design
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Composite Outcome
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
Vascular Risk Associated with Medication-Related Hypoglycemia: Design
Cumulative Incidence of CVD: Hypoglycemia Group vs Control
Cumulative Incidence of Microvascular Complications: Hypoglycemia Group vs Control
Medical Comorbidities Associated with Obesity
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Glycemia, BP, and Dyslipidemia
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Design
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
Diabetes Heart Study: CAC and CVD Mortality
ORIGIN-GRACE: Major Cardiovascular Events
ORIGIN-GRACE: Summary of Findings
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Heart Disease
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Atherosclerosis, Arteriosclerosis, and PAD
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
ALTITUDE: No Reduction in CV, Renal Events with Aliskiren
ONTARGET: Similar CV Outcomes with Ramipril, Telmisartan, and Their Combination
ONTARGET: Significantly Increased Risk of Renal Impairment with Combination Therapy
ONTARGET: Significantly Increased Potassium Level with Combination Therapy
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Design
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
AleCardio: Aleglitazar Safety Vs Placebo
ACC AHA Lifestyle Guidelines Sodium Potassium CHD CVD | NDEI
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Treatment | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy PPT | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy for Black Patients | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Trends in CVD Risk ARIC Study | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI
Reduction in SBP Lowers Cardiovascular Risk in Type 2 Diabetes PPT | NDEI
BP-Lowering Treatment & Macrovascular Outcomes Type 2 Diabetes | NDEI
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
EMPA-REG OUTCOME Empagliflozin Heart Failure Type 2 Diabetes EASD | NDEI
Diabetes Comorbities ADA Guidelines | NDEI PPT
Fatty Liver Disease Is A Diabetes Comorbidity ADA Guidelines | NDEI
Sleep Apnea Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cancer Is A Diabetes Comorbidity ADA Guidelines | NDEI PPT
Fractures Are A Diabetes Comorbidity ADA Guidelines | NDEI
Low Testosterone Is A Comorbidity of Diabetes ADA Guidelines | NDEI
Hearing Impairment Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cognitive Impairment & Diabetes ADA Guidelines Slide | NDEI
Type 2 Diabetes Is Associated With Cardiovascular Outcomes | NDEI
Connection Between Type 2 Diabetes and Heart Failure PPT | NDEI
Relationship Between DPP-4 Inhibitors & Heart Failure Diabetes | NDEI
Key Points from TECOS Subanalysis Sitagliptin DPP-4 | NDEI PPT
No Heart Failure Hospitalization Risk With Sitagliptin in TECOS | NDEI
No Increased Risk of HF Hospitalization, CV Death With Sitagliptin TECOS | NDEI
Effect of DPP-4 Inhibitors Vs Placebo on Heart Failure in Diabetes | NDEI
TECOS No HF Hospitalization Risk With Sitagliptin Treatment Diabetes | NDEI
HOPE-3 Primary Prevention for Individuals at Intermediate CV Risk
HOPE-3 Statin Therapy for Intermediate CV Risk Reduction PPT | NDEI
HOPE-3 CV Event Reduction With Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 LDL & Lipoprotein Reductions With Rosuvastatin Vs Placebo | NDEI
HOPE-3 Safety of Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 Incidence Diabetes With Rosuvatatin Vs Placebo PPT | NDEI
HOPE-3 CV Event Reduction With Antihypertensive Therapy PPT | NDEI
HOPE-3 BP Reductions With Candesartan/HCTZ Vs Placebo PPT | NDEI
HOPE-3 Safety of Candesartan/HCTZ Vs Placebo BP PPT | NDEI
HOPE-3 Cholesterol- and BP-Lowering for Intermediate CV Risk Reduction | NDEI
HOPE-3 Lipid- & BP-Lowering Therapy for Primary Prevention PPT | NDEI
HOPE-3 Lipid- & BP-Lowering Intermediate Risk CV Events PPT | NDEI
HOPE-3 BP-Lowering Arm: Statin Therapy for Intermediate CV Risk Reduction
Liraglutide Cardiovascular Outcomes Trial LEADER Heart Failure PPT | NDEI
IRIS Safety of Pioglitazone Vs Placebo After Stroke or TIA PPT | NDEI